GLPwatch
Papers (9189)
GLP-1 research ranked by citation count, from PubMed + NIH iCite.
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
- GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
- GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
- Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
- Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
- An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers.
- Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.
- GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
- LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
- The Discovery and Development of Liraglutide and Semaglutide.
- Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
- 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
- Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
- The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease.
- Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
- Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study.
- Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
- Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
- Semaglutide lowers body weight in rodents via distributed neural pathways.
- EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.
- Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
- Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
- Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.
- GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK.
- Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.